Compare Gilead Sciences, Inc. (GILD) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Humana Inc — how do they compare? Gilead Sciences, Inc. trades at $133.06 (market cap $163.51B), while Humana Inc trades at $397.7 (market cap $48.96B). The key difference: Gilead Sciences, Inc. is far larger — about 3.3× Humana Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | HUM | |
|---|---|---|
Market Cap | $163.51B | $48.96B |
Sector | Health | Health |
52-Week High | $155.80 | $409.42 |
52-Week Low | $108.22 | $163.67 |
Enterprise Value | $178.05B | $58.00B |
Dividend Yield | 2.49% | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Humana (HUM) trades at $406.70, up 0.17% on the day, and is currently above its consensus price target. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company has beaten earnings expectations for three consecutive quarters and is executing a strategic shift from membership growth to profitability, targeting a 3% Medicare Advantage margin by 2028. Revenue has grown consistently from $92.9B in 2022 to $129.7B in 2025.
The outlook is mixed. The company's strategic pivot and recent contract wins like the Illinois Medicaid contract present growth opportunities. However, significant risks include multiple legal investigations into statements on healthcare costs, declining net profit margins (from 3.02% in 2022 to 0.91% in 2025), and a high P/E ratio of 43.52. Analyst sentiment is cautious, with a majority 'Hold' rating and a consensus price target 13% below the current price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
